Showing 7421-7430 of 7755 results for "".
- New Stelara Data Show Inhibition Of Joint Destruction In Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/20131029-new_stelara_data_show_inhibition_of_joint_destruction_in_psoriatic_arthritis_patients/2459427/New findings from two integrated Phase III Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with ustekinumab (Stelara) resulted in
- Rigel Provides Pipeline Updatehttps://practicaldermatology.com/news/20131024-rigel_provides_pipeline_update/2459429/Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Juvéderm Voluma XC Approved in UShttps://practicaldermatology.com/news/20131023-juvderm_voluma_xc_approved_in_us/2459431/The FDA has approved Juvéderm Voluma XC (Allergan), the first injectable filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. The approval is based on a pivotal clinical trial in the US and Canada demonstrating that Juvéderm Vol
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/20131016-asds_elects_new_officers_board_members/2459435/The American Society for Dermatologic Surgery (ASDS) announces the election of Naomi Lawrence, M.D., as Vice President as well as a new Secretary and three new board members during its Annual Meeting in Chicago. The Society's newly elected officials will join President Mitchel P. Goldman, M.D., and
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- Ellzey Coding Solutions Introduces ICD-10 for Dermatology Manualhttps://practicaldermatology.com/news/20131010-ellzey_coding_solutions_introduces_icd-10_for_dermatology_manual/2459440/Ellzey Coding Solutions, Inc., recently released an ICD-10 coding manual specifically for dermatologists. The 2014 ICD-10 for Dermatology program is a tool that can be used to prepare dermatologists and staff with what they need to know about the ICD-10-CM diagnosis coding syste
- KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stockhttps://practicaldermatology.com/news/20131007-kythera_biopharmaceuticals_announces_proposed_public_offering_of_common_stock/2459441/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $100 million. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA. KYTHERA intend
- Valeant to Help Raise Awareness of Domestic Violencehttps://practicaldermatology.com/news/20131002-valeant_to_help_raise_awareness_of_domestic_violence/2459444/Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) is partnering with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As p